John Stock to Alendronate
This is a "connection" page, showing publications John Stock has written about Alendronate.
Connection Strength
0.733
-
Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr; 40(4):843-51.
Score: 0.270
-
Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. J Clin Densitom. 2005; 8(3):273-7.
Score: 0.236
-
Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013 Mar 23; 13:15.
Score: 0.104
-
Meadows ES, Stock J, Johnston JA. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making. 2006 Nov-Dec; 26(6):633-5; author reply 636-7.
Score: 0.067
-
Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J, Plouffe L. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin. 2004 Mar; 20(3):351-7.
Score: 0.056